Schizophrenia
Conditions
Keywords
schizophrenia, violence risk, long-acting antipsychotics, community-based
Brief summary
This is a 12-month open-label randomized controlled study. Patients with schizophrenia and violence risk under the government supervision will be enrolled in the study. A community-based long-acting antipsychotics-treated management model will be applied to the experimental group, which means that professional psychiatrists will provide guidance to primary-level mental health workers on the psychotic treatment, and monthly-injected long-acting antipsychotic, paliperidone palmitate, will be used in the schizophrenia treatment. Every subject in experimental group will be equipped with an intelligent robot capable at push-to-talk and push-to-view, allowing the patients and caregivers to contact doctors for assistance at any time. The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Subjects in control group will be treated with oral antipsychotics or other conventional medication.
Detailed description
This is a 12-month open-label randomized controlled study. Patients with schizophrenia and violence risk under the government supervision will be enrolled in the study. A community-based long-acting antipsychotics-treated management model will be applied to the experimental group, which means that professional psychiatrists will provide guidance to primary-level mental health workers on the psychotic treatment, and monthly-injected long-acting antipsychotic, paliperidone palmitate, will be used in the schizophrenia treatment. Every subject in experimental group will be equipped with an intelligent robot capable at push-to-talk and push-to-view, allowing the patients and caregivers to contact doctors for assistance at any time, if they are able to use smart phones. The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement. Doctors have rights to decide whether a patient needs in-hospital treatment or extramural hospital treatment. The study protocol does not limit other medication or treatment measures except the injectable paliperidone palmitate. Other medication or treatment measures should be decided according to doctors' clinical judgement and negotiation with patients and guardians. Subjects in control group will be treated with oral antipsychotics or other conventional medication.
Interventions
DRUGpaliperidone palmitate
Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
DRUGcontrol group
Subject in control group will be applied with oral antipsychotics or other conventional medication.
Sponsors
Maosheng Fang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed as schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM-V) and rated under 70 in PANSS; * Had violent behavior such as smashing or breaking, threatening with a weapon, commiting arson or explosion in the past one year, whether the behavior can be stopped by persuading or not; * Living with a guardian or a caregiver; * Informed consent from the patients or their guardians; * Resulted negative in urine pregnancy test if female at their reproductive age; female subjects must take effective measures to prevent pregnancy during the whole study or have been postmenopausal.
Exclusion criteria
* Patients who have had suicidal ideation or suicidal attempts within 12 months before screening or in screening period; * Intravenous drug abuse or Opioid dependence within 3 months before screening; * Patients with treatment-resistant schizophrenia; * Large dose of Clozapine (≥200mg/day) or other long-acting injectable antipsychotics used within 3 months or within 2 drug half-life periods before screening; * Patients with any severe or unstable cardiovascular, respiratory, nervous system or other system diseases; clinically significant abnormality in laboratory examinations or ECG; * Communication difficulties caused by cognitive impairment or unable to complete the assessments in the study; * Patients assessed as unsuitable for the study in other reasons, such as allergic or intolerant to risperidone or paliperidone, resistant to risperidone or paliperidone (ineffective after adequate dosage and duration in medical history); unable to provide informed consent; historical treatments which might effect the results of the study; historical neuroleptic malignant syndrome or tardive dyskinesia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Violence Risk Assessment For Severe Psychiatric Patients | 1 year | The percentage of subjects rated as no or low risk (scored 0 or 1) in Violence Risk Assessment For Severe Psychiatric Patients after 1-year treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Modified Overt Aggression Scale (MOAS) | 1 year | Patients' rated score in Modified Overt Aggression Scale after 1-year treatment |
| Health economic evaluation | 1 year | The patients' and the caregivers' health economic questionnaire after 1-year treatment |
| Positive and Negative Syndrome Scale (PANSS) | 1 year | PANSS total score after 6-month and 1-year treatment |
| Hospitalization frequency | 1 year | Hospitalization frequency after 6-month and 1-year treatment |
| WHO Quality of Life-BREF (WHOQOL-BREF) | 1 year | The patients' and the caregivers' WHOQOL-BREF score after 6-month and 1-year treatment |
| Visual Analogue Scale-100 (VAS 100) | 1 year | The patients' and the caregivers' VAS 100 score after 6-month and 1-year treatment |
| Family Burden Scale of Diseases (FBS) | 1 year | Family burden of the patient's family |
| Personal and Social Performance Scale (PSP) | 1 year | PSP global score after 6-month and 1-year treatment |
| Treatment Emergent Symptom Scale (TESS) | 1 year | Treatment Emergent Symptom Scale (TESS) score after 6-month and 1-year treatment |
| Vital signs | 1 year | Heart rate and blood pressure after 6-month and 1-year treatment |
| Clinical laboratory examination | 1 year | Blood routine examination after 6-month and 1-year treatment |
| Electrocardiogram (ECG) | 1 year | Electrocardiogram (ECG) after 6-month and 1-year treatment |
| Adverse events | 1 year | The frequency of adverse events in the treatment period |
Contacts
Primary ContactYi Lee, Doctor
Backup ContactYang Zhou, Doctor
Outcome results
None listed